Kiadis Announces Results of Annual General Meeting of Shareholders
25 Juin 2020 - 5:50PM
Kiadis Announces Results of Annual General Meeting of Shareholders
Amsterdam, The Netherlands, June 25, 2020 –
Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext
Amsterdam and Brussels: KDS), a clinical-stage
biopharmaceutical company, announces that at its Annual General
Meeting held today at 10:00 CEST, all resolutions were duly passed
by the shareholders.
About KiadisFounded in 1997,
Kiadis is building a fully integrated biopharmaceutical company
committed to developing innovative therapies for patients with
life-threatening diseases. With headquarters in Amsterdam, the
Netherlands, and offices and activities across the United States,
Kiadis is reimagining medicine by leveraging the natural strengths
of humanity and our collective immune system to source the best
cells for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com.
Kiadis Contacts:
Kiadis:Maryann Cimino, Sr. Manager, Corporate
AffairsTel. +1 617 710 7305m.cimino@kiadis.com |
Optimum Strategic Communications:Mary Clark,
Supriya MathurTel: +44 203 950 9144David Brilleslijper
(Amsterdam)Tel: +31 610 942 514kiadis@optimumcomms.com |
Dutch Translation/Nederlandse
vertaling
Amsterdam, Nederland, 25 juni 2020 –
Kiadis Pharma nv ('Kiadis' of de 'vennootschap') (Euronext
Amsterdam en Brussel: KDS), een biofarmaceutisch bedrijf
gericht op onderzoek in de klinische fase, kondigt aan dat alle
resoluties op de jaarlijkse algemene vergadering, die vandaag werd
gehouden om 10.00 uur CEST, werden ondersteund door de
aandeelhouders.
Dit persbericht vormt een vertaling van
het gepubliceerde Engelstalige persbericht. Bij eventuele
verschillen is de tekst van het Engelstalige persbericht altijd
bepalend.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect Kiadis’ or, as appropriate, Kiadis’
officers’ current expectations and projections about future events.
By their nature, forward-looking statements involve a number of
known and unknown risks, uncertainties and assumptions that could
cause actual results, performance, achievements or events to differ
materially from those expressed, anticipated or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
regulation, competition and technology, can cause actual events,
performance, achievements or results to differ significantly from
any anticipated or implied development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or projections,
or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither Kiadis
nor its advisers or representatives nor any of its subsidiary
undertakings or any such person’s officers or employees guarantees
that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.